PureTech Health PlcのIPO年
PureTech Health PlcのIPO年は何ですか。
PureTech Health PlcのIPO年は2015です。
IPO年の定義は何ですか。
新規公開株 (IPO)は、企業の株式を通常は機関投資家に販売し、順番に証券取引所で一般市民に販売する株式公開の一種です。
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
LSEのセクタHealth CareにおけるIPO年の企業と比べるPureTech Health Plc
PureTech Health Plcは何をしますか。
PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and dementia-related psychosis; a hydrogel platform technology to treat obesity and other chronic metabolic diseases; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; a immunomodulation platform to treat chronic and acute inflammatory disorders; therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria; and a digital treatments to treat cognitive dysfunction associated with neurology and psychiatry conditions. It also provides hematopoietic stem cell based therapies to treat hematological malignancies; a voice-based technology platform to measure health when a person speaks; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100, an oral small molecule drug candidate to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210, a IgG1 monoclonal antibody; Glyph, a synthetic lymphatic targeting chemistry platform; milk exosome-based technology to enable the oral administration of macromolecule therapeutic payloads; and meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Roche Holding AG; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
PureTech Health Plcと類似のipo年
- Global BrandsのIPO年は2014です。
- Antibe TherapeuticsのIPO年は2014です。
- ArcelorMittal 5.50% MandatorilyのIPO年は2014です。
- The Toronto-Dominion Bank PFD SER 5のIPO年は2014です。
- WisdomTree EURO STOXX Banks 3x Daily LeveragedのIPO年は2014です。
- Horizons Us Lrg Cap Eqty Cvrd CのIPO年は2014です。
- PureTech Health PlcのIPO年は2015です。
- Larsen & Toubro InfotechのIPO年は2016です。
- Escape Hunt plcのIPO年は2016です。
- SiteOne Landscape Supply IncのIPO年は2016です。
- Lloyds Steels IndustriesのIPO年は2016です。
- Liberty MediaのIPO年は2016です。
- Atlanta Braves IncのIPO年は2016です。